文献速递心境障碍

去甲替林与艾司西酞普兰互换治疗首轮抗抑郁药失败的重性抑郁障碍患者的效果

Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
PubMed 文献 · Br J Psychiatry · 2019-01-30

本研究基于811例接受去甲替林或艾司西酞普兰治疗的重性抑郁障碍成人,其中108例因副作用或无应答而互换药物。互换后MADRS评分显著下降,两个互换方向均显著改善,提示首轮抗抑郁药失败后TCA与SSRI互换可能是可行策略。

要点

  • 首轮抗抑郁药因副作用或无应答失败后,去甲替林与艾司西酞普兰互换可显著降低MADRS评分。
  • 艾司西酞普兰换去甲替林(n=36)和去甲替林换艾司西酞普兰(n=72)均显示显著改善。
  • 因无应答或副作用而互换的患者中,两种互换选项均带来显著改善。

核心结论

  • 首轮抗抑郁药无应答或出现副作用后,TCA与SSRI互换可能是有助于实现应答的可行方法。

研究设计与样本

  • 在811例接受去甲替林或艾司西酞普兰治疗至多12周的重性抑郁障碍成人中,108例因副作用或无应答而互换药物。
  • 互换后随访至多26周,采用MADRS评估应答,并使用校正混合效应线性回归模型(全信息最大似然估计)报告β系数及95%CI。

主要发现

  • 互换抗抑郁药导致MADRS评分显著下降。
  • 艾司西酞普兰换去甲替林者(n=36)的β=-0.38,95%CI -0.51至-0.25,P<0.001。
  • 去甲替林换艾司西酞普兰者(n=72)的β=-0.34,95%CI -0.41至-0.26,P<0.001。
  • 因无应答或副作用而互换的个体中,两种互换选项均带来显著改善。
  • 其他评定量表和症状维度的分析支持上述结果。

关键数值与推荐

  • 互换后MADRS评分显著下降:艾司西酞普兰换去甲替林β=-0.38(95%CI -0.51至-0.25,P<0.001)。
  • 去甲替林换艾司西酞普兰β=-0.34(95%CI -0.41至-0.26,P<0.001)。

临床怎么用

  • 对于首轮抗抑郁药因副作用或无应答失败的重性抑郁障碍患者,可考虑在TCA与SSRI之间互换。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with major depressive disorder (MDD) experiencing side-effects or non-response to their first antidepressant, little is known regarding the effect of switching between a tricyclic antidepressant (TCA) and a selective serotonin reuptake inhibitor (SSRI).AimsTo compare the switch between the TCA nortriptyline and the SSRI escitalopram. METHOD: Among 811 adults with MDD treated with nortriptyline or escitalopram for up to 12 weeks, 108 individuals switched from nortriptyline to escitalopram or vice versa because of side-effects or non-response (trial registration: EudraCT No.2004-001723-38 (https://eudract.ema.europa.eu/) and ISRCTN No.03693000 (http://www.controlled-trials.com)). Patients were followed for up to 26 weeks after switching and response was measured with the Montgomery-Åsberg Depression Rating scale (MADRS). We performed adjusted mixed-effects linear regression models with full information maximum likelihood estimation reporting β-coefficients with 95% CIs. RESULTS: Switching antidepressants resulted in a significant decrease in MADRS scores. This was present for switchers from escitalopram to nortriptyline (n = 36, β = -0.38, 95% CI -0.51 to -0.25, P<0.001) and from nortriptyline to escitalopram (n = 72, β = -0.34, 95% CI -0.41 to -0.26, P<0.001). Both switching options resulted in significant improvement among individuals who switched because of non-response or side-effects. The results were supported by analyses on other rating scales and symptom dimensions. CONCLUSIONS: These results suggest that switching from a TCA to an SSRI or vice versa after non-response or side-effects to the first antidepressant may be a viable approach to achieve response among patients with MDD.Declarations of interestK.J.A. holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the Government of Alberta. K.J.A. has been a member of various advisory boards, received consultancy fees and honoraria, and has received research grants from various companies including Johnson and Johnson Pharmaceuticals Research and Development and Bristol-Myers Squibb Pharmaceuticals Limited. D.S. has served on advisory boards for, and received unrestricted grants from, Lundbeck and AstraZeneca. A.F. and P.M. have received honoraria for participating in expert panels for Lundbeck and GlaxoSmithKline.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Köhler-Forsberg O, Larsen ER, Buttenschøn HN, et al. Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. Br J Psychiatry. 2019. PMID: 30698114. doi:10.1192/bjp.2018.302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。